IBB Consulting ApS

IBB Consulting can support your drug development program with substantial preclinical safety experience covering small molecule and biologic drug candidates, including peptides, mAbs, bispecific mAbs, ADC, DART, RIT within a multitude of indications. Previous assignments include indications of oncology, vaccines, imaging agents, haemophilia, metabolic diseases, growth disorder, CNS, cardiovascular and inflammatory diseases as well as disorders due to calcification or protein misfolding. 

History

Before starting IBB Consulting in May 2017, Ingrid headed up the Toxicology and Safety Pharmacology department at Novo Nordisk A/S for 9 years, since 2014 as Vice President. In this function, Ingrid together with her team guided more than 30 drug development projects successfully into clinical trials, overlooked 100+ non-clinical sections of INDs/IMPDs, and several new compounds were approved for marketing in US and EU.

"Analytical thinking and finding solutions to scientific challenges trigger my enthusiasm and I thrive working together with ambitious, result-orientated teams. My international educational background (DVM - Germany, PhD - Australia,  DVSC - Denmark), employment in industry as well as academia and my publication list document a strong international scientific track record".

Achievements

Since 2017, IBB Consulting has succesfully supported nonclincial safety programs, Scientific Advice meetings, Clinical Trial Applications and BLA submissions for clients like Y-mAbs Therapeutics, FluoGuide, Sanifit,  MonTa BioSciences, Symphogen, Hemab, Evaxion, Antag Therapeutics, Gubra  and others.

Let's talk about your next project, needs or challenges